

Vyvgart (efgartigimod alfa-fcab) Non-Oncology Treatment Order Set

1. Patient Name: _____

2. DOB: _____ Height (inches): _____ Weight (lbs): _____

3. Diagnosis:

- ☐ G70.00 Myasthenia Gravis without acute exacerbation
☐ G70.01 Myasthenia Gravis with acute exacerbation
☐ G61.81 Chronic Inflammatory Demyelinating Polyneuritis
☐ Other ICD-10 Code: _____ Diagnosis description: _____

HOACNY will obtain authorization for drug administration prior to scheduled infusion. If HOACNY is unable to obtain insurance authorization due to this medication not being in alignment with the insurance plan's medical policy, referring office will be notified and HOACNY will not be able to administer the medication.

4. Pre-medications:

- ☐ Acetaminophen: ☐ 1000mg PO ☐ 500mg PO
☐ Diphenhydramine: ☐ 25mg PO ☐ 50mg PO ☐ 25mg IV ☐ 50mg IV
☐ Hydrocortisone: 100mg IVP
☐ Other Pre-medication: _____
☐ No Pre-medications indicated

5. Drug Order:

Vyvgart (efgartigimod alfa-fcab) *Ok to substitute with generic/biosimilar*

- ☐ **Patients weighing less than 120kg:** 10mg/kg IV weekly for 4 weeks, then 4 weeks off x3(G70)
☐ **Patients weighing 120kg or more:** 1200mg IV weekly for 4 weeks, then 4 weeks off x3(G70)
☐ Efgartigimod alfa hyaluronidase: 1,008mg/11,200 units SQ Weekly for 4 weeks (G70)
☐ Efgartigimod alfa hyaluronidase: 1,008mg/11,200 units SQ Weekly (G61.81)
☐ Special Instructions: _____
☐ New to Therapy
☐ Continuing therapy: Last Dose Received _____ Next Dose Due _____

HOA of CNY is responsible to provide nursing care, safe drug handling & administration, post-infusion observation & management of drug hypersensitivity reactions per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in condition or delayed adverse events that occur after leaving the infusion center are to be reported to the prescribing physician for evaluation & management. The prescribing physician is responsible for educating the patient of potential risks & complications associated with drug administration as well as drug specific monitoring parameters before proceeding with Non-Oncology Infusion Referral

6. Infusion Lab Requirements:

- ☐ CBC prior to each subsequent infusion
☐ Other: _____
☐ No lab monitoring indicated

HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMINISTRATION.

The prescribing physician is responsible for ordering, obtaining, reviewing all laboratory results & providing copy to HOACNY prior to infusion as ordered above.

7. Required Baseline Lab/Testing completed:

- ☐ CBC, date: _____ ☐ Positive Anti-Acetylcholine receptor Antibody (AChR) (only G70), date: _____
☐ MG-ADL score (only G70): _____ ☐ MFGA classification score (only G70): _____
☐ IgG level, date (only G70): _____ ☐ Other: _____

8. Patient Assistance & REMS Program Enrollment

- ☐ Yes, patient has been enrolled in _____ program. (Provide Copy Enrollment Forms)
☐ No, patient has not been enrolled in any programs.

Physician's Name: _____ Phone: _____

Physician's Signature: _____ Date: _____

(This drug administration order form is valid for 12 months)